ArticleVirchows Archiv : an international journal of pathology2026
Utility of RB1 immunohistochemistry for prognostic subtyping of pulmonary large cell neuroendocrine carcinoma.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TROP2 immunoreactivity in pulmonary large cell neuroendocrine carcinoma.Histopathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an aggressive and molecularly heterogenous cancer with poorly defined treatment strategies. We aimed to (i) assess whether RB1 immunohistochemistry alone can prognostically stratify LCNEC, (ii) determine whether adding p53, p16 and/or cyclin D1 immunohistochemistry to RB1 improves prognostic stratification, and (iii) perform a systematic review of RB1 status as a predictive marker for guiding chemotherapy regimen selection for LCNEC. A tissue microarray containing 59 archival pure pulmonary LCNEC resections was used for immunohistochemistry. Recurrence free survival (RFS) and disease specific survival (DSS) data were retrospectively assessed. Tumor responses to platinum etoposide versus other chemotherapy regimens were used in a pooled analysis with published study data. RB1 loss on immunohistochemistry was identified in 58% of cases. Among the tumors with RB1 loss, 94% had mutant-pattern p53. In multivariable analyses, retained RB1 was independently associated with longer disease-free survival of patients with advanced stage disease (HR 0.27, 95% CI 0.11-0.64, P = 0.0031). The addition of p53, p16 or cyclin D1 for subgrouping did not improve prognostic stratification. Prior studies on association of RB1 status with differential response to chemotherapy regimens had contrasting results. Overall, we find that RB1 loss assessed via immunohistochemistry is a poor prognostic factor for advanced stage LCNEC, and therefore may aid in identification of carcinomas likely to have small cell carcinoma-like behavior.
Indexed as
Identifiers
41699273What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.